BIIB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
2.7B
+10.4%
2.5B
+8.7%
2.3B
-10.1%
2.5B
-4.2%
2.6B
Cost of Revenue
776.9M
+17.5%
661.0M
+33.4%
495.5M
-26.5%
674.4M
+11.5%
605.0M
Gross Profit
2.0B
+7.8%
1.8B
+1.8%
1.8B
-4.1%
1.9B
-8.8%
2.0B
Operating Expenses
1.8B
+27.4%
1.4B
-15.8%
1.7B
+32.8%
1.3B
+1.7%
1.2B
R&D
693.6M
+21.0%
573.0M
-21.7%
731.8M
+67.0%
438.2M
-1.7%
445.6M
SG&A
709.7M
+16.9%
607.3M
-11.0%
682.5M
+14.7%
594.8M
+1.9%
583.8M
Operating Income
150.9M
-62.0%
397.4M
+303.9%
98.4M
-83.4%
591.4M
-25.4%
792.7M
EBITDA
554.9M
-9.0%
609.7M
+84.9%
329.7M
-59.1%
806.6M
-19.3%
999.5M
Net Income
97.5M
-69.5%
319.5M
+753.4%
-48900000
-110.5%
466.5M
-26.5%
634.8M
EPS (Basic)
$0.66
-69.6%
$2.17
+757.6%
$-0.33
-110.4%
$3.18
-26.6%
$4.33
EPS (Diluted)
$0.66
-69.3%
$2.15
+751.5%
$-0.33
-110.4%
$3.17
-26.8%
$4.33
Shares (Diluted)
148.7M
+0.2%
148.4M
+0.3%
148.0M
+0.6%
147.1M
+0.3%
146.7M
Biogen (BIIB) โ€” Financials